A snp of NPC1L1 affects cholesterol absorption in Japanese

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 4, 2010, Pages 356-360

  Maeda, Tomomi ^a   Honda, Akira ^b   Ishikawa, Toshio ^a   Kinoshita, Makoto ^a   Mashimo, Yamato ^a   Takeoka, Yoko ^a   Yasuda, Daijiro ^a   Kusano, Jun ^a   Tsukamoto, Kazuhisa ^c   Matsuzaki, Yasushi ^b   Teramoto, Tamio ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cholesterol absorption; Ezetimibe; Genotype; NPC1L1

Indexed keywords

CAMPESTEROL; CHOLESTEROL; EZETIMIBE; LATHOSTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; NIEMANN PICK TYPE C1 LIKE 1 PROTEIN; SITOSTEROL; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANADA; CARBOHYDRATE ABSORPTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; JAPANESE; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; TRANSCRIPTION INITIATION SITE;

EID: 77953489801     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.2451     Document Type: Article

References (19)

1. Basic findings of cardiovascular disease (1980/1990/2000) The ministry of Health, Labor and Welfare of Japan
2. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Kita T: Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb, 2004; 12: 98-106
3. Results from USDA's 1994-96 Continuing Survey of Food Intakes by Individuals and 1994-96 Diet and HealthKnowledge Survey
4. Egusa G, Yamane K: Lifestyle, serum lipids and coronary artery disease: comparison of Japan with the United States. J Atheroscler Thromb, 2004; 6: 304-312
5. Scott MG: Absorption and metabolism of dietary cholesterol. Ann Rev Nutr, 1983; 3: 71-96
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278
7. Miida T, Hirayama S, Nakamura Y: Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb, 2004; 11: 253-264
8. Davis HR, Veltri EP: Zetia: Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb, 2007; 14: 99-108
9. Davis HR, Zhu LJ, Hoos LM, Tetzloff G, Maquire M, Liu J, Yao X, Iyer SP, Lam MH, Lund EG, Detmers PA, Graziano MP, Altmann SW: Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and key modulator of whole-body cholesterol homeostasis. J Biol Chem, 2004; 279: 33586-33592
10. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maquire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004; 303: 1201-1204
11. Hegele RA, Guy J, Ban MR, Wang J: NPC1L1 haplotype is associated with inter-individual variation in plasma lowdensity lipoprotein response to ezetimibe. Lipids Health Dis, 2005; 12: 4-16
12. Wang J, Williams CM, Hegele RA: Compound hetero-zygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin Genet, 2005; 67: 175-177
13. Friedewald WT, Levy RI, Fredrickson DD: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
14. Honda A, Yamashita K, Hara T, Ikegami T, Miyazaki T, Shirai M, Xu G, Numazawa M, Matsuzaki Y: Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res, 2009; 50: 350-357
15. Honda A, Yamashita K, Shirai M, Ikegami T, Xu G, Numazawa M, Hara T, Matsuzaki Y: Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. J Lipid Res, 2008; 49: 2063-2073
16. Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, Hobbs HH: Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA, 2006; 103: 1810-1815
17. Simon JS, Karnoub MC, Devlin DJ, Arreaza MG, Qiu P, monks SA, Severino ME, Deutsch P, Palmisano J, Sachs AB, BayneML, Plump AS, Schadt EE: Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics, 2005; 86: 648-656
18. Fahmi S, Yang C, Esmail S, Hobbs HN, Cohen JC: Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait gene. Hum Mol Genet, 2008; 17: 2101-2107
19. Chen CW, Hwang JJ, Tsai CT, Su YN, Hsueh CH, Shen MJ, Lai LP: The g-762T>C polymorphism of the NPC1L1 gene is common in Chinese and contributes to a higher promoter activity and higher serum cholesterol levels. J Hum Genet, 2009; 54: 242-247